Pharmacotherapeutic options for the management of myocardial infarction.
The pharmacological treatment of acute coronary syndrome (ACS), including unstable angina, non-ST- and ST-segment elevation myocardial infarction (MI) is dynamic and continues to evolve. Expert guidelines based on the results of clinical trials for the management of different types of ACS have been published. In both ST-segment elevation and non-ST-segment elevation MI, aspirin/clopidogrel, heparin/low molecular weight heparin/direct thrombin inhibitors, beta-blockers and angiotensin converting enzyme inhibitors are part of the routine regimens. In patients with ST-segment elevation MI, eligibility for thrombolytic therapy needs to be determined and utilised as soon as possible. In patients with non-ST-segment elevation MI, the risks of thrombolytic therapy outweigh the benefits. The use of glycoprotein IIb/IIIa inhibitors has become increasingly important. The use of antihyperlipidaemic agents for the prevention of secondary events in both types of patients continue to be essential and the early aggressive use of lipid-lowering therapy also plays a role in improving endothelial function and stabilising atherosclerotic plaques.